Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 53,206	$ 65,613	$ 170,528	$ 205,823
Research and development related success payments and contingent consideration	(5,497)	(82,615)	4,566	(55,816)
General and administrative	14,052	19,183	46,763	52,515
Total operating expenses	61,761	2,181	221,857	202,522
Loss from operations	(61,761)	(2,181)	(221,857)	(202,522)
Interest income, net	2,579	2,862	8,815	7,212
Other income (expense), net	(742)	303	(4,648)	172
Net income (loss)	$ (59,924)	$ 984	$ (217,690)	$ (195,138)
Net income (loss) per common share - basic	$ (0.25)	$ 0	$ (0.95)	$ (1.01)
Weighted-average number of common shares - basic	235,412	196,978	229,076	193,605
Net income (loss) per common share - diluted	$ (0.25)	$ 0	$ (0.95)	$ (1.01)
Weighted-average number of common shares - diluted	235,412	200,473	229,076	193,605